



US011413308B2

(12) **United States Patent**
Braithwaite et al.(10) **Patent No.:** **US 11,413,308 B2**(45) **Date of Patent:** ***Aug. 16, 2022**(54) **DOSING REGIMEN FOR TREATMENT OF COGNITIVE AND MOTOR IMPAIRMENTS WITH BLOOD PLASMA AND BLOOD PLASMA PRODUCTS**(71) Applicant: **Alkahest, Inc.**, San Carlos, CA (US)(72) Inventors: **Steven P. Braithwaite**, Redwood City, CA (US); **Eva Czirr**, Foster City, CA (US); **Ian Gallager**, Half Moon Bay, CA (US); **Nina Huber**, Redwood City, CA (US); **S. Sakura Minami**, San Francisco, CA (US)(73) Assignee: **Alkahest, Inc.**, San Carlos, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **17/097,702**(22) Filed: **Nov. 13, 2020**(65) **Prior Publication Data**

US 2021/0060063 A1 Mar. 4, 2021

Related U.S. Application Data

(63) Continuation of application No. 16/432,114, filed on Jun. 5, 2019, now Pat. No. 10,874,692, which is a continuation of application No. 15/961,618, filed on Apr. 24, 2018, now Pat. No. 10,357,513.

(60) Provisional application No. 62/490,519, filed on Apr. 26, 2017, provisional application No. 62/584,571, filed on Nov. 10, 2017, provisional application No. 62/623,468, filed on Jan. 29, 2018, provisional application No. 62/641,194, filed on Mar. 9, 2018.

(51) **Int. Cl.****A61K 35/16** (2015.01)**A61P 25/28** (2006.01)**A61K 9/00** (2006.01)**A61K 38/17** (2006.01)**A61K 38/01** (2006.01)(52) **U.S. Cl.**CPC **A61K 35/16** (2013.01); **A61K 9/0026** (2013.01); **A61K 38/017** (2013.01); **A61K 38/1722** (2013.01); **A61P 25/28** (2018.01)(58) **Field of Classification Search**CPC **A61K 38/38**; **A61K 35/16**; **A61P 25/28**; **A61P 25/00**

See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**4,900,720 A 2/1990 Kotitschke
5,916,202 A 6/1999 Haswell
6,632,174 B1 10/2003 Breznitz6,946,546 B2 9/2005 Vaughan et al.
7,785,601 B2 8/2010 Schaebitz et al.
7,851,446 B2 12/2010 Roura
2002/0143283 A1 10/2002 Braverman et al.
2002/0151064 A1 10/2002 Rothenberg et al.
2003/0157687 A1 8/2003 Greene et al.
2004/0120937 A1 6/2004 Wilson
2004/0127445 A1 7/2004 Liew et al.
2004/0141946 A1 7/2004 Schaebitz et al.
2004/0254152 A1 12/2004 Monje et al.
2005/0221348 A1 10/2005 Ray et al.
2006/0094064 A1 5/2006 Ray et al.
2006/0198851 A1 9/2006 Basi et al.
2006/0263759 A1 11/2006 Alves-Filho et al.
2007/0037200 A1 2/2007 Ray et al.
2007/0155725 A1 7/2007 Li et al.
2007/0190055 A1 8/2007 Ambati
2008/0026485 A1 1/2008 Hueber et al.
2008/0057590 A1 3/2008 Urdea et al.
2009/0111740 A1* 4/2009 Grifols Roura A61K 38/38 514/1.1
2009/0143394 A1 6/2009 Wyss-Coray et al.
2009/0181008 A1 7/2009 Ray et al.
2009/0239241 A1 9/2009 Ray et al.
2010/0080850 A1 4/2010 Hubbel et al.
2010/0124756 A1 5/2010 Ray et al.
2010/0258496 A1 10/2010 Hidaka et al.
2010/0310609 A1 12/2010 Watson et al.
2010/0324079 A1 12/2010 Ohyagi

(Continued)

FOREIGN PATENT DOCUMENTSEP 19930184040 B1 4/1993
EP 2111868 B1 8/2013

(Continued)

OTHER PUBLICATIONSCastellano et al, Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. *Nature*, (Apr. 27, 2017) vol. 544, No. 7651, pp. 488-492. Electronic Publication Date: Apr. 19, 2017 (Year: 2017).*Baker et al, Aerobic exercise reduces phosphorylated tau protein in cerebrospinal fluid in older adults with mild cognitive impairment. *Alzheimer's and Dementia*, (Jul. 2015) vol. 11, No. 7, Supp. Suppl. 1, pp. P324 (Year: 2015).*Adair et al., "Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease." *Stroke* Jun. 2004;35(6):e159-62.Adkins et al., "Toward a Human Blood Serum Proteome", (2002) *Molecular & Cellular Proteomics* 1: 947-955.

(Continued)

Primary Examiner — Qiuwen Mi(74) *Attorney, Agent, or Firm* — Mandar A. Joshi; Bret E. Field; Bozicevic, Field & Francis LLP(57) **ABSTRACT**

Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as cognitive disorders. The methods relate to a regimen of pulsed dosing of blood plasma or blood plasma fractions.

19 Claims, 49 Drawing Sheets

(56)

References Cited**U.S. PATENT DOCUMENTS**

2011/0117100	A1	5/2011	Britschgi et al.
2011/0202284	A1	8/2011	McReynolds et al.
2011/0212854	A1	9/2011	Ray et al.
2011/0243947	A1	10/2011	Doody et al.
2012/0095000	A1	4/2012	Wyss-Coray et al.
2012/0258075	A1	10/2012	Wyss-Coray et al.
2013/0040844	A1	2/2013	Wyss-Coray et al.
2013/0302322	A1	11/2013	Wong et al.
2014/0011689	A1	1/2014	Sandip et al.
2014/0121438	A1	6/2014	Quirk
2014/0255424	A1	9/2014	Wyss-Coray et al.
2015/0079045	A1	3/2015	Kong
2015/0157664	A1	6/2015	Wyss-Coray et al.
2016/0143996	A1	5/2016	Wyss-Coray et al.
2016/0208011	A1	7/2016	Wyss-Coray et al.
2017/0081415	A1	3/2017	Wong et al.
2017/0232118	A1	8/2017	Wyss-Coray et al.
2018/0110839	A1	4/2018	Bell et al.

FOREIGN PATENT DOCUMENTS

JP	2016-539992	A	12/2016
RU	2428997	C1	9/2011
RU	2470677	C1	12/2012
UA	35656	C2	4/2001
WO	WO2005052592	A2	6/2005
WO	WO2005106492	A2	11/2005
WO	WO2006133423	A1	12/2006
WO	WO2007059135	A2	5/2007
WO	WO2009023814	A2	2/2009
WO	WO2009055729	A1	4/2009
WO	WO2009155069	A1	12/2009
WO	WO2011094535	A2	8/2011
WO	WO2013142135	A1	9/2013
WO	WO2013184646	A2	12/2013
WO	WO2015088915	A1	6/2015
WO	WO2016187217	A2	11/2016
WO	WO2016205004	A2	12/2016
WO	WO2017120461	A1	7/2017
WO	WO2018200560	A1	11/2018

OTHER PUBLICATIONS

- Anderson et al., "The Human Plasma Proteome", (2002) *Molecular & Cellular Proteomics* 1: 845-867.
- Anderson et al., "High resolution two-dimensional electrophoresis of human plasma proteins", (1977) *Proc. Natl. Acad. Sci.* vol. 74, No. 12, pp. 5421-5425.
- Baba et al., "Timp-3 deficiency impairs cognitive function in mice." *Lab Invest.* Dec. 2009;89(12):1340-7.
- Berezovskaya et al., "Colony stimulating factor-1 potentiates neuronal survival in cerebral cortex ischemic lesion." *Acta Neuropathol.* Nov. 1996;92(5):479-86.
- Boissonneault et al., "Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease." *Brain.* Apr. 2009;132(Pt 4):1078-92.
- Bouchard et al., "Aging and brain rejuvenation as systemic events," *J. Neurochem.* Jan. 2015; 132(1):5-19.
- Britschgi et al., "Blood protein signature for the early diagnosis of Alzheimer disease." *Arch Neurol.* Feb. 2009;66(2):161-5.
- Cheung et al., "Serum β -2 microglobulin predicts mortality in people with diabetes." *Eur J Endocrinol.* May 17, 2013;169(1):1-7.
- Fedoroff et al., "Role of colony stimulating factor-1 in brain damage caused by ischemia." *Neurosci Biobehav Rev.* Mar. 1997;21(2):187-91.
- Gowing et al., "Macrophage colony stimulating factor (M-CSF) exacerbates ALS disease in a mouse model through altered responses of microglia expressing mutant superoxide dismutase." *Exp Neurol.* Dec. 2009;220(2):267-75.
- Jha, "Young blood can reverse some effects of ageing, study finds," *The Guardian*, Oct. 17, 2012, 4 pages.
- Kwak et al., "Aging, exercise, and extracellular matrix in the heart." *J Exerc Rehabil.* Jun. 30, 2013;9(3):338-47.
- Lin et al., "Discovery of a cytokine and its receptor by functional screening of the extracellular proteome." *Science.* May 9, 2008;320(5877):807-11.
- Luo et al., "Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival." *J. Exp. Med.* (2013) 210(1):157-172.
- Lysaght et al., "Beta-2 microglobulin removal during continuous ambulatory peritoneal dialysis (CAPD)." *Perit Dial Int.* 1989;9(1):29-35.
- Malkki, "Ageing: Could young blood combat age-related cognitive decline?" *Nat. Rev. Neurol.* Jun. 2014;10(6):307.
- Manzo et al., "Role of chemokines and chemokine receptors in regulating specific leukocyte trafficking in the immune/inflammatory response." *Clin Exp Rheumatol.* Jul.-Aug. 2003;21(4):501-8.
- McLaurin et al., "Microglial priming to the brain." *Nat Med.* Dec. 2010;16(12):1380-1.
- Middeldorp et al., "A young systemic environment reverses degeneration in a mouse model of Alzheimer's disease," *Neuroscience* 2012, Presentation Abstract, Oct. 16, 2012, 2 pages.
- Mitrasinovic et al., "Microglia overexpressing the macrophage colony-stimulating factor receptor are neuroprotective in a microglial hippocampal organotypic coculture system." *J Neurosci.* Apr. 27, 2005;25(17):4442-51.
- Mizuno et al., "Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid- β neurotoxicity." *Am J Pathol.* Oct. 2011;179(4):2016-27.
- Palop et al., "A network dysfunction perspective on neurodegenerative diseases." *Nature.* Oct. 19, 2006;443(7113):768-73.
- Prakasam et al., "Amyloid and neurodegeneration: Alzheimer's disease and retinal degeneration." Chapter 7, *Handbook of Neurochemistry and Molecular Neurobiology*, Lajtha ed., 2009, 131-163. (Year: 2009).
- Ron-Harel et al., "Age-Dependent Spatial Memory Loss Can Be Partially Restored by Immune Activation," *Rejuvenation Research* (2008), 11(5):903-13.
- Royer et al., "A novel antagonist of prostaglandin O_2 blocks the locomotion of eosinophils and basophils." *Eur J Clin Invest.* Sep. 2008;38(9):663-71.
- Schwartz et al., "How Do Immune Cells Support and Shape the Brain in Health, Disease, and Aging?" *The Journal of Neuroscience*, Nov. 6, 2013, 33(45):17587-96.
- Sellebjerg et al., "Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation." *Eur J Neurol.* Dec. 2009;16(12):1291-8.
- Shin et al., "Association of eotaxin gene family with asthma and serum total IgE." *Hum Mol Genet.* Jun. 1, 2003;12(11):1279-85.
- Skovronsky et al., "Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications." *Annu Rev Pathol.* 2006;1:151-70.
- Smith et al., " β 2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis." *Nat Med.* Aug. 2015;21(8):932-7.
- Strobel et al., "Chicago: the vampire principle—young blood rejuvenates aging brain?" *Alzheimer Research Forum* (Nov. 2009), p. 1-3.
- Stubbs et al., "Indomethacin causes prostaglandin O_2 -like and eotaxin-like selective responses in eosinophils and basophils." *J Biol Chem.* Jul. 19, 2002;277(29):26012-20.
- Teixeira et al., "Increased serum levels of CCL 11/eotaxin in schizophrenia." "Process in neuro-psychopharmacology & biological psychiatry," vol. 32, No. 3, pp. 710-714, 2008.
- Thomson et al., "Young blood for a keener mind," *New Scientist* (2012), 216(2887): 10.
- Villeda et al., "Changes in the systemic milieu modulate neurogenesis during aging." Abstract, 39th Annual Neuroscience Meeting, Chicago, IL, Society for Neuroscience, Oct. 2009, 1-2. (Year: 2009).